Vigencell reported positive top‑line phase II results for VT‑EBV‑N, an antigen‑specific cytotoxic T‑cell therapy for natural killer T‑cell lymphoma (NKTCL), and intends to seek conditional approval in South Korea. Company leadership described the program as the first clinical success for an NKTCL‑targeting cell therapy and signaled rapid regulatory engagement and commercialization planning both domestically and internationally.